Financial Data and Key Metrics Changes - Boston Scientific reported 16.5% organic growth and 22% EPS growth for FY 2024, with a strong start to FY 2025 showing 18% organic growth and 34% EPS growth in Q1 [1][2] - The company raised its full-year guidance to 12-14% organic growth and enhanced its EPS and margin profile despite tariff impacts [4][5] Business Line Data and Key Metrics Changes - The weighted average market growth rate for Boston Scientific has improved from around 1% years ago to approximately 8% currently, driven by a focus on innovation and faster-growing markets [7][8] - The discontinuation of the Accurate neo two product is expected to impact full-year sales by about $200 million, but the company maintains its guidance for Q2 and full-year sales and adjusted EPS [15][16] Market Data and Key Metrics Changes - The overall health of the med tech market remains resilient, with Boston Scientific positioned in high-growth markets such as electrophysiology (EP) and left atrial closure (LAC) [6][8] - The company has successfully navigated macro headwinds, including tariffs and regulatory changes, maintaining strong patient volume due to aging demographics [9][10] Company Strategy and Development Direction - Boston Scientific aims to be the highest-performing med tech company, focusing on enhancing its market growth rate and delivering differentiated results over the next five years [4][21] - The company is investing heavily in its portfolio to position itself for future growth, particularly in the EP and LAC markets [21][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges and emphasized the strength of its global team and supply chain [10][12] - The company anticipates continued growth in the FerriPulse product line, with expectations for PFA to exceed 60% of global AF ablations by 2026 [48][49] Other Important Information - The company has a robust venture capital portfolio that supports its growth strategy, with successful acquisitions contributing to its market position [88][90] - The launch of the FerriPulse product has been described as one of the best in med tech history, with significant market potential and positive feedback from healthcare professionals [35][39] Q&A Session Summary Question: Can you provide an update on the tariff situation? - The company has seen better news regarding tariffs, which is beneficial for its operations, and will provide updates in the second quarter [12][13] Question: What is the impact of discontinuing the Accurate neo two product? - The decision was made due to increased regulatory requirements, but the company expects to meet its sales and EPS guidance despite the financial impact [15][16] Question: How does the company view its growth prospects in the next few years? - Management believes the company will exceed its previous growth guidance and is focused on enhancing its market position and product portfolio [20][21] Question: What is the significance of the CHAMPION trial for WATCHMAN? - The CHAMPION trial aims to demonstrate the efficacy of WATCHMAN compared to oral anticoagulants, which could significantly expand the market for left atrial appendage closure [77][78] Question: How does Boston Scientific plan to compete in interventional cardiology without a TAVR asset? - The company is focusing on its strengths in coronary interventions and has a comprehensive portfolio that addresses unmet needs in the market [79][82]